<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-F2QK6IQD</identifier><date>2018</date><creator>Ovčariček, Tanja</creator><relation>documents/doc/F/URN_NBN_SI_doc-F2QK6IQD_001.pdf</relation><relation>documents/doc/F/URN_NBN_SI_doc-F2QK6IQD_001.txt</relation><format format_type="issue">1</format><format format_type="volume">22</format><format format_type="type">article</format><format format_type="extent">str. 18-22</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">2990715</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-F2QK6IQD</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">adverse events</subject><subject language_type_id="eng">checkpoints inhibitors</subject><subject language_type_id="eng">immunotherapy</subject><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="slv">neželeni učinki</subject><subject language_type_id="slv">zaviralci kontrolnih točk</subject><title>Imunoterapija</title><title>Imunotherapy</title><title>new drugs, different adverse events</title><title>nova zdravila, drugačni sopojavi</title></Record>